



**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q83855

Masakatsu KAWAKAMI

Appln. No.: 10/509,622

Group Art Unit: 1652

Confirmation No.: 1024

Examiner: Iqbal Hossain Chowdhury

Filed: September 29, 2004

For: NOVEL OXIDASE

**STATEMENT OF SUBSTANCE OF INTERVIEW**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Please review and enter the following remarks summarizing the telephonic interview conducted on September 20, 2006. Present at the interview were Examiners Chowdury and Prouty, and Mark Hayman, the Applicants' representative.

An Examiner's Interview Summary Record (PTO-413) has been received.

During the interview, Applicants' representative inquired as to whether claim 2 was objected to as indicated in the Office Action. Examiner's Prouty and Chowdury indicated that claim 2 is not objected to and is allowable.

During the interview, Applicants' representative inquired as to whether the following new claim would be allowable:

14. A screening method, comprising:  
(1) contacting a test substance with a cell expressing a recombinant polypeptide, said polypeptide consisting of the amino acid sequence of SEQ ID

STATEMENT OF SUBSTANCE OF INTERVIEW  
Application No. 10/509,622

Attorney docket Q83855

NO:2, wherein said polypeptide produces O<sub>2</sub><sup>-</sup>, increases expression of TNF- $\alpha$ , and/or increases expression of COX-2;

(2) determining whether said test substance inhibits at least one of: (i) said production of O<sub>2</sub><sup>-</sup>, (ii) said increase in expression of TNF- $\alpha$ , and (iii) said increase in expression of COX-2; and

(3) selecting a substance capable of inhibiting at least one of: (i) said production of O<sub>2</sub><sup>-</sup>, (ii) said increase in expression of TNF- $\alpha$ , and (iii) said increase in expression of COX-2.


Applicants' representative communicated the belief that such a claim overcomes all outstanding rejections. Examiners Chowdhury and Prouty agreed, but suggested that the complete names for TNF- $\alpha$  and COX-2 appear in the claim.

Agreement was reached that claim 2 and new claim 14 would then be allowable.

It is respectfully submitted that the instant STATEMENT OF SUBSTANCE OF INTERVIEW complies with the requirements of 37 C.F.R. §§1.2 and 1.133 and MPEP §713.04.

**It is believed that no petition or fee is required.** However, if the USPTO deems otherwise, Applicant hereby petitions for any extension of time which may be required to maintain the pendency of this case, and any required fee, except for the Issue Fee, for such extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,

  
\_\_\_\_\_  
Mark L. Hayman  
Registration No. 51,793

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE  
23373  
CUSTOMER NUMBER

Date: September 29, 2006